首页 › 基金 › Sanofi › TRAX

Sanofi 对 TRAX 的持仓历史

FIRST TRACKS BIOTHERAPEUTICS · 医疗保健

Sanofi 在 Q3 2026 的 13F 申报中披露持有 TRAX(FIRST TRACKS BIOTHERAPEUTICS)821,917 股,市值约 US$29.1M,约占其申报组合的 4.62%,在其申报持仓中市值排名第 8 位。 Sanofi 最近 2 个申报季度中有 2 个季度披露了 TRAX 持仓,最早可追溯至 Q2 2026。

最新持仓 (Q3 2026)821.92K 股
申报持仓市值$29.13M
组合权重4.62%
首次申报Q2 2026
最近变动持有
更新于2026-11-05

最后更新: 2026-11-05 · 来源: SEC EDGAR Form 13F-HR

Sanofi 对 TRAX 的持仓演变

Sanofi 于 Q2 2026 首次披露 TRAX 持仓:821,917 股(约 US$16.5M)。 该持仓在 Q3 2026 达到峰值 821,917 股,市值约 US$29.1M。 在 2 次申报中,Sanofi 的持股数量始终未变。 最近一期申报(Q3 2026)显示持股 821,917 股、市值约 US$29.1M。

逐季持仓明细

季度股数金额变化
Q2 2026 821.92K $16.54M 新进
Q3 2026 821.92K $29.13M 持有

折线上的点按变动类型着色;缺失季度表示该季未申报持仓。

关于 TRAX 与 13F 数据

TRAX(FIRST TRACKS BIOTHERAPEUTICS)属于医疗保健行业。我们追踪的基金中还有 156 只申报持有 TRAX,申报仓位最大的包括:EcoR1 Capital, LLC (US$63.9M), TCG Crossover Management, LLC (US$58.3M), Affinity Asset Advisors, LLC (US$40.9M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 TRAX 的基金

查看 TRAX 的全部基金持有人 →

常见问题

How long has Sanofi held TRAX?

Sanofi has disclosed TRAX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

What is Sanofi's current position in TRAX?

As of Q3 2026, Sanofi holds 821.92K shares of TRAX (FIRST TRACKS BIOTHERAPEUTICS), valued at $29.13M, representing 4.62% of its reported portfolio and ranking #8.

Has Sanofi been buying or selling TRAX?

In the latest 13F filing (Q3 2026), Sanofi held unchanged its position in TRAX. The position peaked in Q3 2026 at 821.92K shares.

Which other funds hold TRAX?

Other major institutional holders of TRAX include EcoR1 Capital, LLC, TCG Crossover Management, LLC, Affinity Asset Advisors, LLC, among 156 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.